DIabetes ResearCh on patient straTification. (WC2011-078)


Starting date: 01/01/2012

Type 2 diabetes mellitus (T2DM) is a highly heterogeneous condition largely because when hyperglycaemia is discovered it is a diagnosis made after exclusion of other known causes. The phenotype of people who develop diabetes is highly variable, as is the rate at which their subsequent diabetes progresses, how they respond to diabetes therapy and who develops micro- and macrovascular complications. This variable development, progression and treatment response of diabetes is likely to reflect subtypes of diabetes with different pathophysiology. In the DIRECT consortium we propose to identify biomarkers to identify subtypes with rapid diabetes development and progression and altered response to diabetes treatments, and surrogate response biomarkers that reflect the underlying disease progression, and develop and use these biomarkers in clinical trials.